EUVIMEDOpdag EUVIMED
Klinische Studie (Phase I)Open access

A Dose‐Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HP501 in Male Chinese Gout Patients with Hyperuricemia

Longxia Chen, Ruilin Ding, Yuanwei Chen, Xinghai Li, Tengqiong Xiong, Hong Chen, Xiaojing Hu, Yi Zhou, Feng Jiang, Qing Peng

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.70101 ↗

At a glance

Klinische Studie (Phase I) in Clinical Pharmacology in Drug Development, 2026. Written by Longxia Chen and 9 co-authors. Institution: Institute of Drug Clinical Trial/GCP Center, The Affiliated Hospital of Southwest Medical University, Luzhou, China. Major MEDLINE topics: Gout, Gout Suppressants, Hyperuricemia, Organic Anion Transporters. 22 references. The full text is freely available in PubMed Central. Funded by: Hinova Pharmaceuticals Inc.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

HP501, a novel highly selective renal urate transporter 1 (URAT1) inhibitor, represents a promising therapeutic option for hyperuricemia. This Phase I study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HP501 in Chinese gout patients. 37 patients with gout and hyperuricemia were enrolled in this single‐center, open‐label, dose‐escalation study. Participants were sequentially assigned to receive HP501 at 60, 80, and 100 mg twice daily (BID) following single‐ and multiple‐dose regimens. Safety assessments, PK parameters, and PD reductions were systematically evaluated. HP501 demonstrated an acceptable safety and tolerability profile across all dose cohorts. The most common adverse events (≥10% of patients) included gout flare (36.1%), prostatic hypertrophy (36.1%), elevated ALT (16.7%), and kidney stones (11.1%), all of which were mild to moderate in severity. PK analysis revealed dose‐proportional increases in Cmax and AUC (60 to 100 mg BID), with corresponding dose‐dependent reductions in serum UA levels. All patients achieved therapeutic UA targets (

Subjects

MeSH terms (MEDLINE)

GoutGout SuppressantsHyperuricemiaOrganic Anion TransportersOrganic Cation Transport ProteinsAdultAgedHumansMaleMiddle AgedArea Under CurveChinaDose-Response Relationship, DrugUric AcidEast Asian PeopleOrganic Chemicals

Author keywords

HP501dose‐escalation studygoutpharmacodynamicspharmacokineticssafety

Substances

Gout SuppressantsOrganic Anion TransportersOrganic Cation Transport ProteinsSLC22A12 protein, humanURAT1 inhibitor HP501Uric AcidOrganic Chemicals

Authors and institutions

  • Institute of Drug Clinical Trial/GCP Center, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
  • Hinova Pharmaceuticals Inc., Chengdu, China.
  • Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.

Funding

  • Hinova Pharmaceuticals Inc

Cite

APA

Chen, L., Ding, R., Chen, Y., Li, X., Xiong, T., Chen, H., Hu, X., Zhou, Y., Jiang, F., & Peng, Q. (2026). A Dose‐Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HP501 in Male Chinese Gout Patients with Hyperuricemia. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70101

Vancouver

Chen L, Ding R, Chen Y, Li X, Xiong T, Chen H, et al. A Dose‐Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HP501 in Male Chinese Gout Patients with Hyperuricemia. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70101

BibTeX
@article{Chen2026,
  author = {Chen, Longxia and Ding, Ruilin and Chen, Yuanwei and Li, Xinghai and Xiong, Tengqiong and Chen, Hong and Hu, Xiaojing and Zhou, Yi and Jiang, Feng and Peng, Qing},
  title = {A Dose‐Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HP501 in Male Chinese Gout Patients with Hyperuricemia},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.70101}
}
Start for free →